Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 10/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827246 | 0.72 | CYP2A6 (0.53) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL191327 | 0.70 | — | — | |
| SCHEMBL2593988 | 0.69 | IDO1 (0.42) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL17800997 | 0.69 | IDO1 (0.75) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL27880327 | 0.68 | IDO1 (0.67) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| Ethylene SCHEMBL17502485 | 0.67 | CYP3A4 (0.62) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL10616083 | 0.67 | HDAC1 (0.42) | MAPTNPSR1 | |
| SCHEMBL26265591 | 0.67 | CYP11B1 (0.85) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL1925009 | 0.65 | CYP2A6 (1.00) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 | |
| SCHEMBL26260218 | 0.65 | CYP11B1 (0.82) | CYP3A4CYP2E1CYP2D6CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324761-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4374929-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4323070-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | disclosed |
| EP-4281078-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | Lupin Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116723843-A | Pharmaceutical combination of SOS1 inhibitors for the treatment and/or prevention of cancer | 鲁宾有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116535412-A | Polycyclic compounds as SOS1 inhibitors | 昆药集团股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20130331422-A1 | METHODS AND DEVICES FOR USING ISOPERILLY ALCOHOL | NEONC TECHNOLOGIES INC. (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEO ONCOLOGY INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-1846410-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | Bristol-Myers Squibb Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086464-A2 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-1992013092-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF HEMATOPOIETIC GROWTH FACTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| WO-1992013063-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF GROWTH FACTOR GENES AND GROWTH FACTOR RECEPTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203828-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | CYP3A4 67/4885CYP2E1 88/4885CYP2D6 240/4885 |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, PLIN1 | CYP3A4 375/4885CYP2E1 90/4885CYP2D6 538/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | CYP3A4 3770/4885CYP2E1 1051/4885CYP2D6 3125/4885 |
| US-11786521-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | CYP3A4 3770/4885CYP2E1 1051/4885CYP2D6 3125/4885 |
| US-20130331422-A1 | METHODS AND DEVICES FOR USING ISOPERILLY ALCOHOL | ADH1C, CPT1A, ADH5 | CYP3A4 215/4885CYP2E1 6/4885CYP2D6 223/4885 |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | CYP3A4 67/4885CYP2E1 88/4885CYP2D6 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.